Paris, as the epicenter of European medical research and home to the Assistance Publique – Hôpitaux de Paris (AP-HP), represents one of the most sophisticated markets for Point-of-Care (PoC) Molecular Diagnostics. The shift from centralized laboratory testing to rapid, near-patient diagnostics is accelerating across the Île-de-France region, driven by the need for faster clinical decisions in emergency departments, oncology clinics, and infectious disease centers.
Our role as a primary manufacturer and supplier for the Paris market is defined by our ability to meet the rigorous CE-IVDR (In Vitro Diagnostic Regulation) standards. In a city where precision medicine is no longer a luxury but a standard of care, our molecular diagnostic analysis systems provide the analytical sensitivity and specificity required to detect pathogens and genetic biomarkers with unprecedented accuracy.
The roadmap for molecular diagnostics in the next five years is focused on three pillars: Miniaturization, Automation, and Connectivity. For the Paris industrial and medical sectors, this means integrating AI-driven analytics with rapid nucleic acid amplification technologies (NAAT).
Moving beyond traditional PCR, our upcoming modules for the Paris market utilize LAMP technology, allowing for molecular detection at a constant temperature, reducing power consumption and hardware footprint—ideal for mobile clinics in the Paris metropolitan area.
Our systems are being upgraded with cloud-ready interfaces to sync directly with the French "Dossier Médical Partagé" (DMP), ensuring that PoC results are instantly accessible to specialists across Paris hospitals.
Next-generation molecular sensing using CRISPR-Cas9 proteins for ultra-high sensitivity detection of oncology biomarkers, a key focus for our R&D collaboration with European biotech hubs.
Shenzhen BioX Medical Co., Ltd. is a professional manufacturer specializing in molecular diagnostic analysis systems, genetic testing solutions, and clinical laboratory equipment. Established in 2017, the company is headquartered in Shenzhen, China, a leading center for biotechnology innovation, medical device development, and advanced manufacturing.
With a modern manufacturing facility covering more than 9,000 square meters and a workforce of over 200 employees, BioX Medical is dedicated to the research, development, production, and supply of molecular diagnostic technologies for clinical laboratories, hospitals, research institutions, public health organizations, and biotechnology companies worldwide.
The company's product portfolio includes molecular diagnostic analysis systems, nucleic acid testing platforms, genetic analysis systems, pathogen detection solutions, biomarker analysis equipment, automated laboratory testing systems, and precision medicine support technologies. By integrating advanced automation, data management capabilities, and laboratory workflow optimization, BioX Medical develops solutions designed to improve testing efficiency, analytical accuracy, and operational reliability.
Supported by a multidisciplinary team of engineers, laboratory specialists, and quality management professionals, the company continuously invests in innovation and product development. Comprehensive quality control procedures are implemented throughout design, manufacturing, testing, and inspection processes to ensure consistent performance and compliance with international industry standards.
In the post-pandemic era, supply chain resilience is the most critical factor for Paris healthcare providers. Shenzhen BioX Medical leverages the unique "Silicon Valley of Hardware" ecosystem to ensure a stable supply of high-purity reagents and diagnostic hardware.
Shenzhen BioX Medical Co., Ltd. serves customers across Europe, North America, Asia-Pacific, the Middle East, Latin America, and Africa. Our global footprint allows us to cross-pollinate best practices from different healthcare systems, bringing the efficiency of Asian manufacturing to the high-standard requirements of the Paris medical community.
Committed to advancing modern laboratory technologies, BioX Medical focuses on delivering reliable, scalable, and innovative diagnostic systems that support disease detection, genetic analysis, clinical research, and precision healthcare initiatives. Through continuous technological advancement and customer-oriented development, the company strives to contribute to the global evolution of molecular diagnostics and laboratory medicine.
For Paris-based clinics, automated Chemiluminescence Immunoassay (CLIA) and rapid NAAT (Nucleic Acid Amplification Test) platforms are ideal due to their high throughput and compliance with EU diagnostic standards.
We maintain a rigorous quality management system certified under ISO 13485. Each product destined for France undergoes extensive validation to meet the specific requirements of the European In Vitro Diagnostic Regulation (IVDR).
Yes, we work with established distributors in the Île-de-France region to provide on-site installation, training, and 24/7 technical maintenance for our molecular diagnostic systems.
Leveraging our Shenzhen supply chain, standard lead times are 5-7 working days via air freight, with all necessary customs documentation pre-prepared for French authorities.
Get in touch with our specialist team for a customized molecular diagnostic consultation.
Send Inquiry Now
BioX Medical
